Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516442 | 0.92 | HDAC8 (0.84) | HDAC8MAPTLY96ACHEHDAC3 | |
| SCHEMBL16516560 | 0.91 | HDAC8 (0.87) | HDAC8MAPTLY96ACHEHDAC3 | |
| SCHEMBL16516641 | 0.90 | HDAC8 (0.73) | HDAC8MAPTAPPLY96ACHE | |
| SCHEMBL16516649 | 0.89 | HDAC8 (0.72) | HDAC8MAPTAPPLY96HDAC3 | |
| SCHEMBL18559977 | 0.88 | HDAC8 (0.69) | HDAC8MAPTAPPLY96ACHE | |
| SCHEMBL18538447 | 0.88 | HDAC8 (0.65) | HDAC8MAPTAPPPTPN1NPC1 | |
| SCHEMBL21064508 | 0.87 | HDAC8 (0.70) | HDAC8HDAC3HDAC1 | |
| SCHEMBL16516744 | 0.83 | HDAC8 (1.00) | HDAC8MAPTLY96HDAC3HDAC1 | |
| SCHEMBL16516663 | 0.83 | PARP10 (0.60) | HDAC8MAPTAPPLY96HDAC3 | |
| SCHEMBL1550021 | 0.83 | HDAC8 (0.65) | HDAC8MAPTAPPPTPN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
| CN-105979941-A | Photo composition and position guidance in an imaging device | 希望之城 | 2016-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885MAPT 3015/4885APP 4751/4885 |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885MAPT 3015/4885APP 4751/4885 |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885MAPT 3015/4885APP 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.